Predict your next investment

Public-Private Partnership
techtransferupv.com

See what CB Insights has to offer

Investments

4

About Tech Transfer UPV

Tech Transfer UPV is the first technology transfer fund powered by a Spanish public university.

Tech Transfer UPV Headquarter Location

Edificio CPI – 8E (Cubo Amarillo) 3ª Planta Camino de Vera s/n

Valencia, 46022,

Spain

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tech Transfer UPV News

Spanish medtech startup QUIBIM closes €8 million investment round

Jul 23, 2020

Spanish medtech startup QUIBIM closes €8 million investment round Published: 22-07-2020 14:43:00 | By: Pie Kamau | hits: 41 | Tags: Spanish Medtech startup QUIBIM has closed €8 million new financing in a seed funding round co-led by Amadeus Capital Partners and Adara Ventures, with participation by Apex Ventures, Partech, Crista Galli Ventures and existing shareholders, including Tech Transfer UPV, managed by Clave Capital and Juan Roig. QUIBIM specialises in radiomics, the extraction of standardised, quantitative information from medical imaging data sets using artificial intelligence (AI). QUIBIM’s medical image postprocessing and extraction of imaging biomarkers enables hospitals and pharmaceutical companies to detect diseases early and systematically. QUIBIM has already launched more than 20 algorithms for a range of conditions including cancer, Alzheimer’s, osteoarthritis and liver disease. It has recently launched chest X-ray and CT scan products for COVID-19. QUIBIM Precision®, its proprietary platform, extracts and quantifies disease-specific biomarkers from medical images with ultra-high accuracy. Its products are used in over 70 hospitals and 11 clinical trials across the world, with 600,000 analyses and 6.5 million images processed to date. QUIBIM was founded by  Dr. Ángel Alberich-Bayarri  and  Prof. Luis Marti-Bonmati , two innovators at the forefront of medical imaging. They established the process for the development of biomarkers, adopted in 2013 by the European Society of Radiology (ESR) as the official industry standard. They again set a benchmark when, in March 2020, QUIBIM became the main AI platform for screening for COVID-19 across  Europe . Shortly after, the Radiological Society of North America (RSNA), with more than 52,000 members from 153 countries, joined the initiative with the goal of creating a global medical repository of COVID-19 cases, with the European arm running on QUIBIM Precision®. By incorporating AI technologies, QUIBIM also improves the performance and workflow of radiology departments. The company is launching its qp-Suites product family, designed to support radiologists by centralising the essential tools for clinical diagnosis in one platform, increasing operational efficiency. Angel Alberich Bayarri , founder and CEO of QUIBIM said: “QUIBIM is now at a scale-up point ready to grow internationally while maintaining great science at the core of our mission. This latest round of funding will be used to boost the AI platform, our available algorithms and high-value components, to provide a seamless, all-in-one solution supporting healthcare providers. Our new investors will open opportunities for us in new markets and help us to strengthen our brand internationally. We will be able to promote our new prostate, musculoskeletal and oncology solutions and increase sales globally, by expanding our workforce over the coming year.” Pierre Socha , Partner, Amadeus Capital Partners added: “We are excited by the potential of radiomics to improve disease detection and enable precision treatments guided by imaging biomarkers. QUIBIM’s all-in-one platform is the answer that radiologists have been waiting for and we look forward to helping them grow internationally while continuing the fight against COVID-19 and other life-threatening conditions.” Rocio Pillado , partner at Adara Ventures said: “QUIBIM’s rapid adoption is an indicator of how innovative doctors and researchers are eager to have access to and exploit AI technology and methods that can automatically recognise complex patterns in imaging data, to get quantitative assessments and improve the service they provide.'' Legal advisers on the investment were  Garrigues  and  Araoz&Rueda .

Tech Transfer UPV Investments

4 Investments

Tech Transfer UPV has made 4 investments. Their latest investment was in QUIBIM as part of their Seed VC - II on July 7, 2020.

CBI Logo

Tech Transfer UPV Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/21/2020

Seed VC - II

QUIBIM

$9.2M

No

4

1/16/2019

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

7/27/2017

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

12/28/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/21/2020

1/16/2019

7/27/2017

12/28/2016

Round

Seed VC - II

Unattributed VC

Unattributed VC

Seed VC

Company

QUIBIM

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$9.2M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.